HANDS Act

The HANDS Act (HR 5120) requires Medicare, Medicaid, and TRICARE to cover opioid overdose reversal drugs (such as naloxone) at no cost for patients at risk of opioid overdose who are being discharged from hospitals, emergency departments, or ambulatory surgical centers. Starting January 1, 2026, these drugs must be provided at the time of discharge along with administration instructions, eliminating all cost-sharing (like deductibles or copays) for eligible patients. The bill defines "preventive opioid overdose reversal drugs" as intranasal or intramuscular medications administered by healthcare providers (e.g., doctors or nurses) to at-risk patients during discharge. This policy aims to increase access to life-saving medication at critical care transition points without mandating provider administration.